. Author manuscript; available in PMC: 2021 Jun 18.

Published in final edited form as: Eur Respir J. 2021 Feb 11;57(2):2000337. doi: 10.1183/13993003.00337-2020

TABLE 3.

Association of the methotrexate (MTX) ever-use with rheumatoid arthritis (RA)-related interstitial lung disease (ILD), according to chest high-resolution computed tomography (HRCT) scan patterns

	Discovery			Pooled replication^#			Combined^#
	RA-UIP	RA-nonUIP	RA-noILD	RA-UIP	RA-nonUIP	RA-noILD	RA-UIP	RA-nonUIP	RA-noILD
Patients	47	42	165	133	177	508	180	219	673
MTX ever-use	26 (55.3)	28 (66.7)	137 (83.0)	100 (75.2)	147 (83.1)	485 (95.5)	126 (70.0)	175 (79.9)	622 (92.4)
OR_adj (95% CI)	0.44 (0.20–0.98)	0.41 (0.18–0.95)		0.25 (0.11–0.59)	0.48 (0.20–1.12)		0.36 (0.19–0.61)	0.44 (0.24–0.81)
Adjusted p-value	0.044	0.038		0.002	0.090		0.0003	0.008

Data are presented as n or n (%), unless otherwise stated. UIP: usual interstitial pneumonia; RA-noILD: RA patients without ILD. The RA-UIP subset includes RA-ILD patients with the following HRCT scan patterns: UIP and possible UIP. The RA-nonUIP subset includes RA-ILD patients having the following HRCT scan patterns: nonspecific interstitial pneumonia, organising pneumonia, unclassifiable ILD. Adjusted odds ratios (OR_adj) and their corresponding p-values are adjusted for age at RA onset, sex, ever-smoking, biologic ever-use, MTX exposure duration and periods of MTX use at year of RA onset, and obtained by random-effects meta-analysis of pooled estimates over multiply imputed datasets. OR_adj are adjusted odds ratios for RA-UIP or RA-nonUIP versus RA-noILD.

^#:

UK excluded from the pooled replication and combined analyses.